Showing results (421-430 of 887) with videos related to
Sort By:
Pageof 89
Molecular Genetics and Metabolism|May 19, 2023
An expert consensus on the recommendations for the use of biomarkers in Fabry diseaseAlessandro Burlina, Eva Brand, Derralynn Hughes, et al.Circulation. Cardiovascular Genetics|January 8, 2014
Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry diseaseMarkus Niemann, Arndt Rolfs, Stefan Störk, et al.Journal of the American Society of Nephrology : JASN|December 1, 2001
Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damageKerstin Amann, Aurelia Simonaviciene, Tatiana Medwedewa, et al.Kidney & Blood Pressure Research|May 16, 2018
Different Relevance of Peripheral, Central or Nighttime Blood Pressure Measurements in the Prediction of Chronic Kidney Disease Progression in Patients with Mild or No-ProteinuriaPiotr Kuczera, Katarzyna Kwiecień, Marcin Adamczak, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 2, 2008
Acute phase reaction to gadolinium-DTPA in dialysis patientsHenning Steen, Evangelos Giannitsis, Claudia Sommerer, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|January 13, 2006
Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetesMarie-Luise P Gross, Andreas Koch, Bernd Mühlbauer, et al.European Heart Journal|September 11, 2019
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trialDavid Fitchett, Silvio E Inzucchi, Christoph Wanner, et al.The Lancet. Diabetes & Endocrinology|July 2, 2017
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trialDavid Z I Cherney, Bernard Zinman, Silvio E Inzucchi, et al.Scientific Reports|August 27, 2020
Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitusMichael Müller, Carl-Ludwig Schönfeld, Tanja Grammer, et al.Kidney International|March 1, 2016
Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysisVera Krane, Kay-Renke Schmidt, Lena J Gutjahr-Lengsfeld, et al.Pageof 89